

JOHN M. BROOKS, Ph.D.

University of South Carolina
Arnold School of Public Health
Center for Effectiveness Research in Orthopaedics (CERortho)
915 Greene Street, Suite 303D
Columbia, SC 29208
Phone: (803) 777-9224
Fax: (803) 777-1836
Email: john-brooks@sc.edu

26 McRae Place
Simpsonville, SC 29681
(864) 454-2159

I. HIGHER EDUCATION (least to most recent)

| <u>Institution</u> | <u>Dates Attended</u> | <u>Field of Study</u> | <u>Degree</u> | <u>Award Date</u> |
|--|-----------------------|-----------------------|---------------|-------------------|
| 1. Michigan State University | 1978-1982 | Economics | B.A. | 6/82 |
| 2. University of North Carolina @ Greensboro | 1982-1984 | Economics | M.A. | 8/84 |
| 3. University of Michigan | 1987-1993 | Economics | Ph.D. | 12/93 |

II. ACADEMIC AND PROFESSIONAL EXPERIENCE (least to most recent)

| <u>Title of Position</u> | <u>Institution</u> | <u>Dates of Service</u> | <u>Main Courses Taught</u> |
|--------------------------|--|-------------------------|----------------------------|
| 1. Teaching Assistant | University of North Carolina at Greensboro | 1982-1983 | Statistics |
| 2. Research Assistant | University of North Carolina at Greensboro | 1982-1983 | |
| 3. Instructor | Elon College | 1984 | Microeconomics |
| 4. Research Economist | Battelle Pacific Northwest Laboratories | 1984-1985 | |
| 5. Consultant | Data Resources, Inc. | 1985-1987 | |
| 6. Research Assistant | Vector Research, Inc. | 1987-1993 | |
| 7. Teaching Assistant | University of Michigan | 1989-1991 | Microeconomics |
| 8. Instructor | University of Maryland Baltimore County | 1995-1996 | Health Economics |
| 9. Service Fellow | Agency for Healthcare | 1993-1996 | |

Policy and Research

| | | | |
|---|---|-----------------|---|
| 10. Assistant Professor | University of Iowa College of Pharmacy | 1996 to 2002 | Pharmaceutical Socioeconomics Theory I & II; Health Care Systems |
| 11. Associate Professor | University of Iowa College of Pharmacy College of Public Health | 2002 to 2010 | Pharmaceutical Socioeconomics Theory I & II; Economics and Drug Choice; Analytical Methods |
| 12. Professor | University of Iowa College of Pharmacy College of Public Health | 2010 to 2013 | Pharmaceutical Socioeconomics Theory I; Economics and Drug Choice; Analytical Methods |
| 13. Professor & SC SMARTstate Endowed Chair | University of South Carolina | 2013 to Present | Effectiveness Methods |

III. HONORS, AWARDS, RECOGNITIONS AND OUTSTANDING ACHIEVEMENTS (least to most recent)

1. 1990 **Michigan Economics Society, Outstanding Teaching Assistant Award.**
2. 1991-1992 **Veterans Administration Dissertation Fellowship.**
3. 1992-1993 **Veterans Administration Dissertation Fellowship.**
4. 1997-1998 **Faculty Development Award in Pharmacoeconomics**, Pharmaceutical Research and Manufacturers of America Foundation.
5. 1999 **Best Contributed Podium Presentation**, International Society for Pharmacoeconomics and Outcomes Research Meeting.
6. 2005 **Teacher of the Year (P3 class)**, University of Iowa College of Pharmacy.
7. 2006 **High Impact Factor Poster Presentation**, International Society for Pharmacoeconomics and Outcomes Research Meetings, Philadelphia, PA
8. 2009 **Invited Testimony.** Institute of Medicine Committee on Comparative Effectiveness Research Priorities, March 20, 2009.

9. 2008-2009 **Agency for Healthcare Research and Quality**, Co-Chair of the Comparative Effectiveness Framework Committee.
10. 2012 **Acknowledged High Quality Reviewer**, by the Journal *Pharmacoepidemiology and Drug Safety*
11. 2012-2017 **Member**, Agency for Healthcare Research and Quality, Healthcare Systems & Value Research (HSVR) Study Section.

IV. RECORD OF TEACHING ACTIVITIES

A. Teaching Assignments (least to most recent)

UNIVERSITY OF SOUTH CAROLINA

| <u>Semester/Year</u> | <u>Course Number, Title</u> | <u>Enrollment</u> | <u>Responsibility</u> |
|----------------------|--|-------------------|---|
| Fall 2014 | HSPM 720 Health Services Research Methods II 3 cr. elective | 7 + 8 audits | lecturer 14 3-hour lectures |
| Fall 2015 | HSPM 720 Health Services Research Methods II 3 cr. Elective | 2 + 2 audits | lecturer 14 3-hour lectures |
| Fall 2016 | HSPM 720 Health Services Research Methods II 3 cr. Elective | 9 + 3 audits | lecturer 14 3-hour lectures |
| Fall 2017 | HSPM 720 Health Services Research Methods II 3 cr. elective | 6 + 2 audits | lecturer 14 3-hour lectures |
| Fall 2018 | HSPM 720 Health Services Research Methods II 3 cr. Elective | 5 + 2 audits | lecturer 14 3-hour lectures |
| Fall 2019 | HSPM 720 Health Services Research Methods II 3 cr. elective | 4 | lecturer 14 3-hour lectures |
| Fall 2019 | HSPM 800:002 Seminar: Specific Aims Development 3 cr. elective | 4 | lecturer/discussion 7 2-hour classes |

UNIVERSITY OF IOWA (2007-2012)

| <u>Semester/Year</u> | <u>Course Number, Title</u> | <u>Enrollment</u> | <u>Teaching Responsibility</u> |
|----------------------|--|-------------------|--|
| Spring 2007 | 046:253 Economics and Treatment Choice 3 cr. elective | 45 | lecturer 15 1.5-hour lectures |
| Spring 2007 | 46:264 Theory in Pharmaceutical Socioeconomics II Provider Behavior and Choice 3 cr. required | 2 | course co-coordinator lecturer 8 3-hr lectures |
| Fall 2007 | 46:130 Core Principles in PSE 4 cr. required | 100 | lecturer 9 1-hour lectures 2 1-hour discussions |
| Fall 2007 | 46:263 Theory in Pharmaceutical Socioeconomics I Patient Behavior and Choice 3 cr. required | 8 | course co-coordinator lecturer 8 3-hour lectures |
| Fall 2007 | 173:285 (College of Public Health) Outcomes Research 3 cr. | 15 | lecturer 1 3-hour lecture |
| Fall 2007 | 46:213 Pharmaceutical Socioeconomics: Seminar 1 cr. required | 10 | coordinator |
| Spring 2008 | 046:253 Economics and Treatment Choice 3 cr. elective | 45 | lecturer 15 1.5-hour lectures |
| Fall 2008 | 46:261 Analytical Methods in Health Services Research I 3 cr. required | 12 | course coordinator/lecturer 14 3-hour lectures |
| Spring 2009 | 046:253 Economics and Treatment Choice 3 cr. elective | 45 | lecturer 15 1.5-hour lectures |
| Fall 2009 | 46:263 Theory in Pharmaceutical Socioeconomics Patient Behavior and Choice 3 cr. required | 7 | course co-coordinator lecturer 8 3-hour lectures |
| Fall 2009 | 46:130 | 100 | lecturer |

| | | | |
|-------------|--|-----|--|
| | Core Principles in PSE 4 cr. required | | 7 1-hour lectures 1 1-hour discussions |
| Spring 2010 | 046:253 Economics and Treatment Choice 3 cr. elective | 45 | lecturer 15 1.5-hour lectures |
| Fall 2010 | 46:129 Pharmaceutical Economics and Insurance 4 cr. required | 100 | lecturer 12 1-hour lectures |
| Fall 2010 | 46:261 Analytical Methods in Health Services Research I 3 cr. required | 12 | course coordinator/lecturer 14 3-hour lectures |
| Fall 2011 | 46:263 Theory in Pharmaceutical Socioeconomics Patient Behavior and Choice 3 cr. Required | 12 | course co-coordinator lecturer 8 3-hour lectures |
| Fall 2011 | 46:129 Pharmaceutical Economics and Insurance 4 cr. required | 100 | lecturer 12 1-hour lectures |
| Fall 2012 | 46:129 Pharmaceutical Economics and Insurance 4 cr. required | 100 | lecturer 12 1-hour lectures |
| Fall 2012 | 46:261 Analytical Methods in Health Services Research I 3 cr. required | 12 | course coordinator/lecturer 14 3-hour lectures |

B. Graduate Student Involvement

1. Ph.D. STUDENTS (FACULTY ADVISOR)

| <u>Student</u> | <u>Graduation Date</u> | <u>Project</u> |
|----------------|----------------------------|--|
| Sharash Shetty | 2002 | Atypical Antipsychotic Diffusion in Schizophrenia |
| Tae-Ryong Park | 2004 | Effectiveness of Antibiotics for Otitis Media Using Instrumental Variables |
| Yongming Zhao | 2006 | Effect of Early Nephrology Care on Dialysis Patient Survival |

| | | |
|--------------------------|------|--|
| Xiaoyun Pan | 2010 | Estimation of G-CSF Effectiveness in Reducing Neutropenia Hospitalization Among Non-Hodgkin's Lymphoma Patients Treated with Anthracycline-Based Chemotherapy. |
| Shaowei Wan | 2010 | Investigating the Effects of Access to Cancer Care on Age-Specific Utilization of Chemotherapy Among Elderly Women with Metastatic Breast Cancer |
| Puttarin Kulchaitanaroaj | 2014 | Evaluation of a Physician-Pharmacist Collaboration Intervention for Treating Hypertension |
| Yuxin Tang | 2014 | Investigating Effects of Diagnosing Depression Among Patients with Acute Myocardial Infarction. |
| Cole Chapman | 2014 | Identification of Population Average Treatment Effects Using Nonlinear Instrumental Variable Estimators: Another Cautionary Note |

2. Ph.D. STUDENTS (COMMITTEE MEMBER)

| <u>Student</u> | <u>Graduation Date</u> | <u>Project</u> |
|-----------------|------------------------|--|
| Hong Xiao | 1997 | Impact of Changes in Pharmacy Accessibility on Patient Utilization of Prescription Services |
| Indranil Bagchi | 1998 | Relationship Between Willingness-to-Pay and Measures of Health-Related Quality of Life |
| Madhav Namjoshi | 1998 | The Relationship Between Profile-Based Quality of Life Scores and Utility Scores in Oncology |
| Im-Myung Song | 1998 | Geographic Variation in the Use of New Prescription Drugs: A Diffusion Perspective |
| Jay Meyer | 1999 | A Longitudinal Analysis of the HMO Enrollment Impact on Pharmaceutical Utilization and Expenditures in a Medicaid Population |
| Isaya Sukarom | 1999 | Satisfaction Differentiation Between Pharmaceutical Goods and Services |
| Jane Dewitt | 2000 | The Influence of Parents' Experience and Perceptions on Response to Children's Adverse Drug Reactions |
| Greg Tarquinio | 2001 | A Cost-Effectiveness Simulation of a Fall Prevention |

| (College of Nursing) | | Program |
|--|------|--|
| Jessica Devila (College of Public Health) | 2001 | Evaluating Treatment Variation in for Early-Stage Breast Cancer Patients in Iowa: Physician Characteristics and Patient Variables that Influence Surgical Referral Decisions |
| Shrividya Iyer | 2003 | Influences on Physician Recommendation for Imatinib Mesylate in Chronic Myeloid Leukemia Patients |
| Donald Klepser | 2005 | Does Physician Quality Affect Bargaining Power Over Price in Third Party Contracts? |
| Benjaporn Kingroungret | 2005 | Factors Influencing Reporting the Use of Natural Products to Community Pharmacists |
| George Wehby | 2006 | Prenatal Care Utilization and Its Effects on Infant Health In Samples of Normal Versus Abnormal Births From South America |
| Eun Cho | 2006 | The Effect of the Prescription to Over-the-Counter Switch of Claritin on the Use of Alternative Prescription Allergy Medications. |
| Elizabeth Unni | 2008 | Development of Models to Predict Medication Non-Adherence Based on a New Typology |
| Mary Charlton | 2008 | Evaluation of the Impact of Employer-Sponsored High Deductible Health Plans with Health Savings Accounts on Expenditures, Utilization, and Use of Preventive Services |
| Cormac O'Sullivan | 2008 | The Adoption of Drug-Eluding Cardiac Stent Technology: An Application of Roger's Model |
| Gang Fang | 2011 | The comparative treatment effectiveness and safety of tissue versus non-tissue ace inhibitors among the elderly after acute myocardial infarction |
| Oscar Garza | 2013 | An Action Research Approach to Examining Perceptions and Needs in Diabetes Care in a Community in Mexico Using Innovative Care for Chronic Conditions Framework |
| Fozia Ajmal | 2017 | Association of freestanding dialysis facility size, Quality Incentive Program scores and patient survival |
| Amanda Arnold | 2017 | Patterns of Participation and Performance in Youth Baseball Players |

| | | |
|-----------------|------|--|
| Agha Ajmal | 2018 | Factors Associated with Advance Care Plans and End-of-Life Care Choices among Elderly Americans: An Analysis of Health and Retirement Study Data |
| Gloria Esoimeme | 2019 | The Relationship between the Patient Portal and Shared Decision Making |
| Adam Lutz | 2019 | The Effect of Patient Financial Liability on Physical Therapy Utilization and Patient Reported Outcomes For Patients with Low Back Pain: In Instrumental Variables Analysis. |

3. M.S. STUDENTS (FACULTY ADVISOR)

| <u>Student</u> | <u>Graduation Date</u> | <u>Project</u> |
|--------------------|------------------------|--|
| Chonthira Tinmanee | 2003 | Influence of Geographic Access on Patient's Initial Choice of Chemotherapy for Advanced Non-Hodgkin's Lymphoma |
| An-Chen Fu | 2009 | The Influence of Local Area Physician Supply on the Dispersion of Care Among Medicare Patients with a Consistent Diagnosis |

4. M.S. STUDENTS (COMMITTEE MEMBER)

| <u>Student</u> | <u>Graduation Date</u> | <u>Project</u> |
|------------------|------------------------|--|
| Gina Buban | 1999 | Physician Adoption Behavior of Paclitaxel in Breast Cancer Patients |
| Mitchell Barnett | 1999 | Non-thesis degree |
| Shrividiya Iyer | 2000 | The Relationship Between Entrepreneurial Orientation and Performance in Independent Community Pharmacies |
| Gang Fang | 2004 | The Role of Goal Balancing in Pharmacists' Choice of Service Provision |
| Yin Wan | 2009 | The Relationship Between Hospital Breast Cancer Surgical Volume and 5-Year Survival for Early Stage Breast Cancer Patients |

C. **Other Contributions to Instructional Programs**

PHARM.D. STUDENTS (RESEARCH ROTATIONS & HONORS ADVISING)

| <u>Student</u> | <u>Graduation Date</u> | <u>Project</u> |
|----------------|------------------------|----------------|
|----------------|------------------------|----------------|

| | | |
|-------------------------------|------|--|
| Martin Kluesner | 2001 | Factors That Affect the Use of Stimulants Post-ADHD Diagnosis (American Pharmacist Association Poster Presentation) |
| Jena Steffensmeier | 2003 | Assessing the Extent of Medication Switching Behavior in Iowa Priority Members Following Publication of a Preferred Medication List (American Pharmacist Association Podium Presentation) |
| Ryan Loukota | 2005 | Price Reduction and Market Competition among Medicare Drug Card Programs |
| Michelle O'Connor | 2006 | Association of Hospice Availability and Anthracycline-Based Chemotherapy for Patients with Non-Hodgkin's Lymphoma and Diffuse Large Cell Histology (American Pharmacist Association Poster Presentation) |
| Jessica Black & Leigh Boehmer | 2006 | Association of Provider Availability on Treatment Choices for Elderly Stage IV Lung Cancer Patients |
| Sam Huff | 2010 | Literature Review of the Use of the Chronic Disease Score |
| Dana Newman | 2010 | Time spent by pharmacists providing disease state management for patients in health care clinic settings |
| Jack Mobley | 2020 | Relationship between malpractice laws and treatment choices in orthopaedic conditions. |

PHARM.D. STUDENTS (RESEARCH ROTATIONS)

| | |
|---------------------|------|
| Elizabeth Eggelston | 1997 |
| Martin Kluesner | 2001 |
| Jenna Steffensmeier | 2002 |
| Ryan Loukota | 2005 |
| Michelle O'Connor | 2005 |
| Jessica Black | 2006 |
| Leigh Boehmer | 2006 |
| Sam Huff | 2010 |
| Dana Newman | 2010 |

V. RECORD OF SCHOLARLY ACTIVITIES

A. Publications

PEER-REVIEWED JOURNAL ARTICLES (least to most recent)

1. Hirsch, B, Austin R, **Brooks JM**, Moore B. "Economics Department Rankings: Comment," *American Economic Review*, September 1984, pp 822-826.
2. **Brooks JM**, Kirking D. "Effect of Production Environment on Labor Demand in Veterans Affairs Medical Center Pharmacies." *American Journal of Health-Systems Pharmacy* 52, April 15, 1995, pp 812-822.
3. **Brooks JM**, Dor A, Wong H. "The Hospital-Insurer Bargaining Process: An Empirical Investigation of Appendectomy Pricing." *Journal of Health Economics* 16(4), August 1997, pp 417-434.
4. Doucette W, **Brooks JM**, Sorofman B, Wong H. "Market Factors and the Availability of Community Pharmacy Services," *Clinical Therapeutics* 8, 1999, pp 1267-79.
5. **Brooks JM**, Sorofman B, Doucette W. "Varying Health Care Provider Objectives and Cost-Shifting: The Case of Retail Pharmacy in the U.S." *Health Economics*, 8, 1999, pp 137-150.
6. **Brooks JM**, Doucette W, Sorofman S. "Factors Affecting Bargaining Outcomes Between Pharmacists and Insurers." *Health Services Research*. 34(1), April 1999, Part II, pp. 439-451.
7. **Brooks JM**, McDonough R, Doucette W. "Pharmacist Reimbursement for Pharmaceutical Care Services: Why Insurers May Flinch." *Drug Benefit Trends* 12(6), June 2000, pp 45-56.
8. **Brooks JM**, McClellan M, Wong H. "The Marginal Benefits of Invasive Treatment for Acute Myocardial Infarction: Does Insurance Coverage Matter?" *Inquiry*. 37(1), Spring 2000, pp 75-90.
9. Xiao H., Sorofman B, Manasse H, Taylor T, **Brooks JM**, "Impact of Pharmacy Closures on Patient Use of Prescription Drugs." *Journal of Social and Administrative Pharmacy*, 17, 2000, pp 25-33.
10. **Brooks JM**, Chrischilles E, Scott S, Ritho J, Chen-Hardee S. "Information Gained from Linking SEER Cancer Registry Data to State-Level Hospital Discharge Abstracts." *Medical Care*, 38(11), November 2000, pp 1131-1140.
11. Doucette W, **Brooks JM**, Sorofman B, Hetrick, A. "Bargaining Between Community Pharmacies and Third-Party Payers: Influences on Bargaining Outcomes." *Journal of Managed Care Pharmacy*. 7(1), January/February 2001, pp 43-49.
12. Lund BC, Perry PJ, **Brooks JM**, Arndt S. "Clozapine Use In Patients with Schizophrenia and the Risk of Diabetes, Hyperlipidemia, and Hypertension - A Claims-Based Approach." *Archives of General Psychiatry* 58 (12): December 2001, 1172-1176.
13. **Brooks JM**, Doucette W, Sorofman BS. "Third Party Bargaining and Contract Terms: A Link Over Time." *Journal of the American Pharmaceutical Association* 42(3), May/June 2002. pp 420-27.

14. Klepser ME, Klepser DG, Ernst EJ, **Brooks JM**, Diekema DJ, Mozaffari E, Hendrickson J. "Healthcare Resource Utilization Associated with the Treatment of Penicillin-Susceptible and -Nonsusceptible Isolates of *Streptococcus Pneumoniae*." *Pharmacotherapy* 23(3), March 2003. pp 349-359.
15. Motheral B, **Brooks JM**, Clark MA, Crown WH, Davey P, Hutchins D, Martin BC, Stang P. "A Checklist for Retrospective Database Studies - Report of the ISPOR Task Force on Retrospective Databases" *Value in Health* 6(2), Mar-Apr 2003. pp 90-97.
16. Farris KB, Chrischilles EA, **Brooks JM**, Sorofman BA, Doucette WB. "Commentary on Pharmacist Care Program Increased Patient Satisfaction But Had Little Clinical Benefit for People with Asthma and Chronic Obstructive Pulmonary Disease." *Evidence-Based Healthcare*. 7, 2003, pp 33-35.
17. **Brooks JM**, Chrischilles E, Scott S, Chen-Hardee S. "Was Lumpectomy Underutilized for Early Stage Breast Cancer?" Instrumental Variables Evidence for Stage II Patients from Iowa," *Health Services Research*, 38(6) Part 1, December 2003, pp 1385-1402.
18. Davila JA, **Brooks JM**, Pendergast JF, Chrischilles EA, "The Effect of Physician Characteristics and their Practice Environment on Surgical Referral Patterns for Early-Stage Breast Cancer," *American Journal of Medical Quality*, 19(6) November-December 2004, pp 266-273.
19. Farris KB, Ganther-Urmie JM, Fang G, Doucette WR, **Brooks JM**, Klepser DG, Fries DJ, Kuhle CL, "Population-Based Medication Reviews: A Descriptive Analysis of the Medication Issues Identified in a Medicare Not-for-Profit Prescription Discount Program," *Annals of Pharmacotherapy* 38(1), November 2004, pp 1823-1829.
20. Chrischilles EA, Klepser DG, **Brooks JM**, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ, "Effect of Clinical Characteristics on Neutropenia-Related Inpatient Costs Among Newly Diagnosed Non-Hodgkin's Lymphoma Cases During First-Course Chemotherapy," *Pharmacotherapy* 25 (5), May 2005, pp 668-675.
21. Chen-Hardee SS, Chrischilles EA, Voelker MD, **Brooks JM**, Scott SD, Link BK, Delgado DJ, "Population-based Assessment of Hospitalizations For Neutropenia From Chemotherapy in Older Adults With Non-Hodgkin's Lymphoma" *Cancer Causes and Control* 17(5), June 2006, pp 647-654.
22. Ganther-Urmie JM, Farris KB, Doucette WR, **Brooks JM**, Fries DJ, Kuhle CL. "Medicare Beneficiaries' Satisfaction and Experiences with a Prescription Drug Discount Card and Preferred Drug List: the Iowa Priority Prescription Savings Program." *Journal of the American Pharmacists Association* 46, November/December 2006, pp. 715-722.
23. **Brooks JM**, Irwin C, Hunsicker L, Flanagan M, Chrischilles E, Pendergast J. "Effect of Dialysis Center Profit-Status on Patient Survival: A Comparison of Risk-Adjustment and Instrumental Variable Approaches." *Health Services Research*, 41(6), December 2006, pp. 2267-2289.

24. **Brooks JM**, Klepser DG, Urmie JM, Farris KB, Doucette WR, "Effect of Local Competition on the Willingness of Community Pharmacies to Supply Medication Therapy Management Services," *Journal of Health and Human Services Administration*, 30(1), Summer 2007, pp 4-27.
25. **Brooks JM**, Chrischilles EA. "Heterogeneity and the Interpretation of Treatment Effect Estimates from Risk-Adjustment and Instrumental Variable Methods," *Medical Care* 45(10 supplement), October 2007, pp S123-S130.
26. Park TR, **Brooks JM**, Chrischilles EA, Bergus G. "Estimating the Effect of Treatment Rate Changes When Treatment Benefits are Heterogeneous: Antibiotics and Otitis Media," *Value in Health* 11(2), Mar-Apr 2008, pp 304-314.
27. **Brooks JM**, Doucette WR, Wan S, Klepser DG. "Factors Affecting Retail Pharmacy Market Structure and Performance," *Inquiry* 45(1), Spring 2008, pp 75-88.
28. **Brooks JM**, John E, Klepser DG, Urmie JM, Farris KB, Doucette WR, "Factors Affecting Demand Among Older Adults for Medication Therapy Management Services," *Research in Social and Administrative Pharmacy* 4(4), December 2008, pp 309-319.
29. Titler MG, Herr K, Xie X, **Brooks JM**, Schilling ML, Marsh JL, Summative Index: Acute Pain Management in the Elderly, *Applied Nursing Research* 44(1), Oct 2008, pp 245-263.
30. Fox KM, **Brooks JM**, Kim J. "Metastatic Non-Small Cell Lung Cancer: Costs Associated with Disease Progression," *American Journal of Managed Care* 14(9), September 2008, pp 565-571.
31. Carter BL, Farris, KB, Abramowitz PW, Weetman DB, Kaboli PJ, Dawson JD, James PA, Christensen AJ, **Brooks JM**, "The Iowa Continuity of Care Study: Background and Methods," *American Journal of Health System Pharmacy*, 65(17), 2008, pp 1631-1642.
32. Zhao Y, **Brooks JM**, Chrischilles EA, Pendergast JF, Hunsicker LG, Flanigan M. "Factors Affecting Early Nephrology Care Prior to Hemodialysis Initiation Among Elderly Patients with End-Stage Renal Disease," *Kidney International* 74 (12), 2008, pp 1596-1612.
33. **Brooks JM**, Titler MG, Herr K, Ardery G, Xie X. "The Effect of Evidence-Based Acute Pain Management Practices on Inpatient Cost," *Health Services Research* 44(1), February 2009, pp 245-263.
34. Titler MG, Herr K, **Brooks JM**, Xie X, Ardery G, Schilling ML, Marsh JL, Clarke WR, "Translating Research into Practice Intervention Improves Management of Acute Pain in Older Hip Fracture Patients," *Health Services Research*, 44(1): Feb 2009, 264-87.
35. **Brooks JM**, Fang G. "Estimating Treatment Effects for Binary Outcomes with Choice and Heterogeneity: A Simulation Model," *Clinical Therapeutics*, 31(4), 2009.

36. Fox KM, **Brooks JM**, Gandra SR, Markus R, Chiou C-F. "Estimation of Cachexia Among Cancer Patients Based on Four Definitions," *Journal of Oncology*, 2009, Article ID 693458, 7 pages, doi:10.1155/2009/693458.
37. Zhang S, Doucette WR, Urmie JM, Xie Y, **Brooks JM**, "Factors Associated with Independent Pharmacy Owners' Satisfaction with Medicare Part D Contracts", *Research in Social and Administrative Pharmacy*, 6(2), June 2010, pp 121-129.
38. Fang G, **Brooks JM**, Chrischilles EA. "A New Method to Isolate Local-Area Practice Styles in Prescription Use as the Basis for Instrumental Variables in Comparative Effectiveness Research" *Medical Care*, 48, August 2010, pp 710-717.
39. Keating NL, Landrum MB, **Brooks JM**, Chrischilles EA, Winer EP, Wright K, Volya R. "Outcomes Following Surgery for Early-Stage Breast Cancer in Non-Trial Populations" *Breast Cancer Research and Treatment*, 125, 2011, pp 803-813.
40. Charlton ME, Schneider J, **Brooks JM**, Levy B, High RR, "Effect of Health Savings Accounts on Utilization, Expenditures and Preventive Services", *American Journal of Managed Care*, 17(1), 2011:79-86
41. Link BK, **Brooks JM**, Wright K, Pan X, Voelker M, Chrischilles E, "Diffuse large B-cell Lymphoma in the Elderly: Diffusion of Treatment with Rituximab and Survival Advances With and Without Anthracyclines", *Leukemia and Lymphoma*, 52(6), 2011:994-1002.
42. Fang G, **Brooks JM**, Chrischilles, EA, "Apples and Oranges? Interpretations of Risk Adjustment and Instrumental Variable Estimates of Intended Treatment Effects Using Observational Data", *American Journal of Epidemiology*, 175(1), 2012:60-65.
43. Fang G, **Brooks JM**, Chrischilles, EA, "Comparison of Instrumental Variable Analysis Using a New Instrument with Risk Adjustment Methods to Reduce Confounding by Indication", *American Journal of Epidemiology*, 175(11), 2012:1142-1151.
44. Polgreen LA, **Brooks JM**, "Estimating Incremental Costs with Skew: A Cautionary Note", *Applied Health Economics and Health Policy*, 10(5), 2012:319-29.
45. Fox KM, Yee J, Cong Z, **Brooks JM**, Petersen J, Lamerato L, Gandra SR, "Transfusion Burden in Non-Dialysis Chronic Kidney Disease Patients with Persistent Anemia Treated in Routine Clinical Practice: a Retrospective Observational Study, *BMC Nephrology*, 13(5), 2012: DOI: 10.1186/1471-2369-13-5.
46. Kulchaitanaroaj P, **Brooks JM**, Ardery G, Newman D, Carter BL, "Incremental Costs associated with Physician and Pharmacist Collaboration to Improve Blood Pressure Control", *Pharmacotherapy*, 32(8), 2012:772-780.
47. **Brooks, JM**, Chrischilles EA, Landrum MB, Wright KB, Fang G, Winer EP, Keating NL, "Survival Implications Associated with Variation in Mastectomy Rates for Early-Stage Breast Cancer", *International Journal of Surgical Oncology*, vol. 2012, Article ID 127854, 9 pages, 2012: doi:10.1155/2012/127854.

48. **Brooks JM**, Ohsfeldt RL. "Squeezing the Balloon: Propensity Scores and Unmeasured Covariate Balance", *Health Services Research*, 48(4), 2013: 1487-507.
49. **Brooks JM**, Tang Y, Chapman CG, Cook EA, Chrischilles EA. "What is the Effect of Area Size When Using Local Area Practice Style as an Instrument", *J Clin Epidemiol*. 2013 Aug;66(8 Suppl):S69-83. doi: 10.1016/j.jclinepi.2013.04.008.
50. **Brooks JM**, Cook EA, Chapman CG, Kulchaitanaroaj P, Chrischilles EA, Welch S, Robinson J. "Geographic Variation in Statin Use for Complex Acute Myocardial Infarction Patients Evidence of Effective Care?", *Medical Care*. 2014 Mar;52 Suppl 3:S37-44. doi: 10.1097/MLR.0b013e3182a7fc3d.
51. Cook EA, Schneider KM, Chrischilles, EA, **Brooks JM**, "Accounting for Immeasurable Time Bias when using Medicare Prescription Drug Data", *Medicare Medicaid Res Rev*. 2013 Nov 15;3(4). doi: 10.5600/mmrr.003.04.a01. eCollection 2013.
52. O'Donnell BE, Schneider KM, **Brooks JM**, Lessman G, Wilwert J, Cook EA, Martens G, Chrischilles EA, Wright K, "Standardizing Medicare Payment Information to Support Examining Geographic Variation in Costs", forthcoming in *Medicare & Medicaid Research Review. Medicare Medicaid Res Rev*. 2013 Sep 10;3(3). doi: 10.5600/mmrr.003.03.a06. eCollection 2013
53. **Brooks JM**, Cook EA, Chapman CG, Schroeder MC, Chrischilles EA, Schneider KM, Kulchaitanaroaj P, Robinson JG. Statin Use After Acute Myocardial Infarction by Patient Complexity: Are the Rates Right? *Medical Care. April 2015 53(4): 324-331 doi: 10.1097/MLR.0000000000000322.*
54. Farris KB, Carter BL, Xu Y, Dawson JD, Shelsky C, Weetman DB, Kaboli PJ, James PA, Christensen AJ, **Brooks JM**. "Effect of a Care Transition Intervention by Pharmacists: an RCT. *BMC Health Serv Res*. 2014 Sep 18;14:406. doi: 10.1186/1472-6963-14-406.
55. Kulchaitanaroaj P, Carter BL, Goedken AM, Chrischilles EA, **Brooks JM**. "Instrumental Variable Methods to Assess Quality of Care: The Marginal Effects of Process-of-Care on Blood Pressure Change and Treatment Costs", *Res Social Adm Pharm*. MAR-APR 2015 11(2): E69-E83. doi: 10.1016/j.sapharm.2014.07.007.
56. Tien YY, Link BK, **Brooks JM**, Wright K, Chrischilles E, "Treatment of Diffuse Large B-Cell Lymphoma in the Elderly: Regimens without Anthracyclines are Common and Not Futile". *Leuk Lymphoma*. JAN 2015 56(1):65-71. DOI: 10.3109/10428194.2014.903589
57. Lund BC, Schroeder MC, Middeldorf G, **Brooks JM**, "Impact of Hospitalization on Inappropriate Prescribing in Elderly Medicare Beneficiaries", *Journal of the American Geriatrics Society*. April 2015 63(4):699-707. PMID: 25855518.
58. Schroeder MC, Robinson JG, Chapman CG, **Brooks JM**, "Use of Statins by Medicare Beneficiaries Post Myocardial Infarction: Poor Physician Quality of Patient-Centered Care", *Inquiry*. 52 Feb 2015: 1-5 pii: 0046958015571131. doi: 10.1177/0046958015571131.PMID: 25724749

59. Polgreen LA, Cook EA, **Brooks JM**, Polgreen PM, "Increased Statin Prescribing Does Not Lower Pneumonia Risk", *Clinical Infectious Diseases*, 60(12), June 2015 60(12):1760-6. PMID: 25759433.
60. Tang Y, **Brooks JM**, Wetmore J, Shireman T, "Association between Higher Rates of Cardioprotective Drug Use and Survival in Patients on Dialysis", *Research in Social & Administrative Pharmacy*, 11(6), 2015, 824-843.
61. Chapman CG, **Brooks JM**, Average Causal Treatment Effect Estimation using Nonlinear Two-Stage Instrumental Variable Estimators: Another Cautionary Note, *Health Serv Res*. 51 (6), 2016, 2375-2394.
62. Schroeder MC, Tien Y-Y, Wright K, Halfdanarson T, Abu-Hejleh T, **Brooks JM**, "Geographic Variation in the Use of Adjuvant Therapy Among Elderly Patients with Resected Non-Small Cell Lung Cancer." *Lung Cancer*. 95, 2016:28-34.
63. Chrischilles EA, Schneider K, Schroeder MC, Letuchy E, Wallace RB, Robinson JG, **Brooks JM** "Association of pre-admission functional status with use and effectiveness of secondary prevention medications in elderly survivors of acute myocardial infarction." *Journal of the American Geriatrics Society*, 64(3), March 2016, 526-535.
64. Goedken A.M., Lund B.C., Cook E.A., Schroeder M.C., **Brooks J.M.** "Application of a Framework for Determining Number of Drugs." *BMC Res Notes*. 2016 May 13;9(1):272. doi: 10.1186/s13104-016-2076-5.
65. **Brooks JM**, Chapman CG, Cozad MJ, "The Identification Process Using Choice Theory is Needed to Match Design with Objectives in CER." *Med Care*. 55(2), 2016, 91-93.
66. Cozad MJ Chapman CG, **Brooks JM**, "Specifying a Conceptual Model Including a Treatment Choice Relationship is Necessary for Comparative Effectiveness Research" *Med Care*. 55(2), 2016, 94-96.
67. Chapman CG. Cozad MJ, **Brooks JM**, "Conditions for Generating Treatment Effect Estimates in Line with Objectives: Beyond Confounding" *Med Care*. 55(2), 2016, 97-99.
68. Schroeder MC, Chapman CG, Nattinger MC, Halfdanarson TR, Abu-Hejleh T, Tien YY, **Brooks JM**. Variation in geographic access to chemotherapy by definitions of providers and service locations: a population-based observational study. *BMC Health Serv Res*. 2016 Jul 18;16(1):274. doi: 10.1186/s12913-016-1549-5.
69. Kulchaitanaroaj P, **Brooks JM**, Chaiyakunapruk N, Goedken AM, Chrischilles EA, Carter BL. Cost-utility analysis of physician-pharmacist collaborative intervention for treating hypertension compared with usual care. *J Hypertens*. 2017 35 (1), 178-187.
70. Goedken AM, **Brooks JM**, Milavetz G, Rudzianski NJ, Chrischilles EA, Geographic variation in inhaled corticosteroid use for children with persistent asthma in Medicaid. *Journal of Asthma*, 2018, 55(8):851-858. DOI: 10.1080/02770903.2017.1362428

71. **Brooks JM**, Chapman CG, Suneja M, Schroeder MC, Fravel MA, Schneider KM, Wilwert J, Li YJ, Chrischilles EA, Brenton DW, Brenton M, Robinson J. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right? *Journal of the American Heart Association*, June 2018, 7(11): DOI: 10.1161/JAHA.118.009137.
72. **Brooks JM**, Chapman CG, Schroeder MC, Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous for More Than One Outcome. *Applied Health Economics and Health Policy*, June 2018, 16(3): 381-393, DOI: 10.1007/s40258-018-0380-z.
73. Chapman C, Thigpen C, Floyd SB, **Brooks JM**, Chen B, & Tokish J. Treatment for rotator cuff tear is influenced by demographics and characteristics of the area where patients live. *Journal of Bone & Joint Surgery Open Access*. 2018. 3(3).
74. Floyd SB, Chapman CG, Thigpen C, Tokish, J, Hawkins R, **Brooks JM**. (2018). Shoulder Arthroplasty in the US Medicare Population: a 1-year evaluation of surgical complications, readmissions and revision surgery. *The Journal of Shoulder and Elbow Surgery Open Access*. 2(1), 40-47. DOI: <https://doi.org/10.1016/j.jses.2017.10.002>
75. Thigpen CA, Floyd SB, Chapman CG, Tokish JT, Kissenberth MJ, Hawkins R, **Brooks JM**. Comparison of Surgeon Performance of Rotator Cuff Repair: Risk Adjustment Toward a More Accurate Performance Measure. *Journal of Bone & Joint Surgery - American Volume*, 2018. 100(24): 2110-2117.
76. Floyd SB, Chapman CG, Shanley E, Ruffrage L, Matthia E, Cooper P, **Brooks JM**. A Comparison of One-Year Treatment Utilization for Shoulder Osteoarthritis Patients Initiating Care with Non-Orthopaedic Physicians and Orthopaedic Specialists. *BMC Musculoskeletal Disorders*. 2018. 19(1):349.
77. Ajmal F, Probst J, **Brooks JM**, Hardin J, Qureshi Z. Association between Freestanding Dialysis Facility Size and Medicare Quality Incentive Program Performance Scores, *American Journal of Nephrology*. 2019. 49 (1), 64-73.
78. Floyd SB, Campbell J, Chapman CG, Thigpen CA, Kissenberth MJ, **Brooks JM**. Geographic variation in the treatment of proximal humerus fracture: an update on surgery rates and treatment consensus. *Journal of Orthopaedic Surgery and Research*, 2019, 14(22). DOI: 10.1186/s13018-018-1052-2.
79. Jurewicz KA, Hobbs MA, Neyens DM, Childres AK, Cozad MJ, **Brooks JM**, Identifying the timing and duration of collecting patient priorities in an orthopedic clinic. *Human Factors and Ergonomics in Manufacturing & Service Industries*. 2019. 29(3). 201-209.
80. Lutz AD, **Brooks JM**, Chapman CG, Shanley E, Stout CE, Thigpen CA. Risk-Adjustment of MDQ and NDI to Benchmark Physical Therapists: Analysis of Spine Care from a Physical Therapy Outcomes Registry. *Phys Ther*. 2019. In press.

81. Bell N, Lopez-De A, Cai B, **Brooks JM**, Reliability of the American Community Survey Estimates of Risk-Adjusted Readmission Rankings for Hospitals Before and After Peer Group Stratification, *JAMA Network open* 2 (10), 2019. e1912727-e1912727.
82. Ajmal F, Probst JC, **Brooks JM**, Hardin JW, Qureshi Z, Jafar TH, Freestanding dialysis facility quality incentive program scores and mortality among incident dialysis patients in the United States. *American Journal of Kidney Diseases*, 2019, <https://doi.org/10.1053/j.ajkd.2019.07.023>
83. Shanley E, Thigpen C, **Brooks JM**, Hawkins RJ, Momaya A, Kwapisz A, Kissenberth MJ, Tokish JM, Return to sport as an outcome measure for shoulder instability: surprising findings in nonoperative management in a high school athlete population, *The American Journal of Sports Medicine*, 5(7), pp 1062-1067, 2019.
84. Floyd SB, Thigpen C, Kissenberth MJ, **Brooks JM**, Association of Surgical Treatment With Adverse Events and Mortality Among Medicare Beneficiaries With Proximal Humerus Fracture. *JAMA Network Open*. 2020; 3(1): e1918663. doi:10.1001/jamanetworkopen.2019.18663

PEER-REVIEWED RESEARCH BOOK CHAPTERS

1. **Brooks JM**, Dor A, Wong H. "The Impact of Physician Payments on Hospital-Insurer Bargaining in the US," in *Governments and Health Systems*, John Wiley and Sons; D Chinitz and M. Cohen eds, 1998.
2. Xie Y, **Brooks JM**, Urmie JM, Doucette WR. "Retail Pharmacy Market Structure and Insurer-Independent Pharmacy Bargaining in the Medicare Part D Era," in *Advances in Health Economics, volume 22*, Emerald Group Publishing Limited; ed. Avi Dor, 2010.
3. **Brooks JM**, Supplement 1. Improving Characterization of Study Populations in Observational CER: The Identification Problem, in Developing a Protocol for Observational Comparative Effectiveness Research (OCER): A User's Guide (Prepared by Outcome DEcIDE Center [Quintiles Outcome] under Contract No. HHS290200500161 TO10). In: Velentgas P, Dreyer NA, eds. Vol 12-EHC099. Rockville, MD: Agency for Healthcare Research and Quality; 2012

DISSERTATION

1. **Brooks JM**. *Measuring Cost Efficiency in VA Hospital Pharmacies: An Applied Critique of the Methods*, Ph.D. Dissertation, University of Michigan. 1993.

MASTERS THESIS

1. **Brooks JM**. *Modeling the Determinants of Automobile Market Share: Does Past Performance Matter*, Masters Thesis, University of North Carolina at Greensboro. 1984.

FINAL PROJECT REPORTS

1. Skeer J, Barbera A, **Brooks JM**. *Northern Lights: Economic and Practical Potential of Imported Power from Canada*, US Department of Energy, Office of Policy, Planning and Analysis, DOE Publication # PE-0079, December 1987.
2. **Brooks JM**, Doucette WR, Sorofman BA. *Factors Affecting the Bargaining Power of Pharmacies and Insurers*. final report. Agency for Healthcare Research and Quality contract number RO3-HSO9541-01. 1998.
3. **Brooks JM**, Chrischilles E, Scott S, Ritho J, Chen-Hardee S. *Using Linked Databases to Construct Instrumental Variables Suitable For Early Stage Breast Cancer Treatment Effectiveness Research*. final report. National Cancer Institute contract number NO1-PC-85063-20. 1999.
4. Doucette WR, Hetrick AS, **Brooks JM**, Sorofman BA. *Community Pharmacy Bargaining with Third Party Payers*. final report. National Community Pharmacist Association. 2000.
5. Chrischilles E, **Brooks JM**, Scott S, Chen-Hardee S, Park TR. *Unbiased Outcome Estimates of Early Stage Prostate Cancer from Retrospective Data: An Instrumental Variables Approach*. final report. Department of Defense. contract number DAMD17-98-8486. 2001.
6. Chrischilles E, **Brooks JM**, Chen-Hardee S, Park TR. *Antimicrobial Use and Resistance Prevention Model*. final report. Wellmark Foundation. 2001.
7. Farris KB, **Brooks JM**, Doucette WR, Ganther JM, Fang G, Klepser D, Hiley B, Schneider J, Cummings R, *Impact of the Iowa Priority Brown Bag Medication Review on the Safety, Effectiveness, and Efficiency of Seniors= Medication Use*. final report. Iowa Department of Public Health. October 20, 2003.
8. **Brooks JM**, Doucette WR, Wan S, Klepser DG, "Factors Affecting Retail Pharmacy Market Structure and Performance". Report prepared for the Agency for Healthcare Quality and Research – AHRQ MarketNet Conference, November 10, 2005.
9. **Brooks JM**, Chapman CG, Suneja M, Schroeder MC, Fravel MA, Schneider KM, Wilwert J, Li YJ, Chrischilles EA, Brenton DW, Brenton M, Robinson J. *Understanding Treatment Effect Estimates When Treatment Effects Are Heterogeneous for More Than One Outcome*. Patient Centered Outcomes Research Institute. ME-1303-6011. 2018.
10. **Brooks JM**, Chapman CG, Lutz A, Evaluation of Legacy Patient Reported Outcome Measures as Performance Measures in Rehabilitation Final Report, The Physical Therapy Industry Outcomes Workgroup. 2019

LETTERS TO THE EDITOR

1. **Brooks JM**, Chrischilles E. "Research Highlights the Art of Medicine." *Wall Street Journal*. June 1, 2001:A15.

B.1 Research Support - Completed

FUNDING RECEIVED (least to most recent)

1. Factors Affecting Bargaining Between Pharmacists and Insurers. Principal Investigator: John Brooks. 5% effort 9/1/1997-8/31/1998. Agency for Healthcare Research and Quality. (Total Direct Cost = \$50,000).
2. Faculty Development Award in Pharmacoeconomics. Principal Investigator: John Brooks 60% funded. 8/1/1997-7/31/1999. Pharmaceutical Research and Manufactures of America Foundation. (Total Direct Cost = \$80,000).
3. Using Linked Databases to Construct Instrumental Variables Suitable for Early Stage Breast Cancer Treatment Effectiveness Research. Principal Investigator. John Brooks 15% effort. 7/1/1998-6/30/1999. National Cancer Institute. (Total Direct Cost = \$49,831).
4. Statewide Model of Antibiotic Use and Resistance Prevention. Principal Investigator: Elizabeth Chrischilles. Co-Investigator. 5% effort. 3/30/2000-9/30/2002. Iowa Medical Society/US Department of Health and Human Services. (Total Direct Cost = \$70,500).
5. Community Pharmacy Bargaining with Third Party Payers. Principal Investigator: William Doucette. Co-Investigator. 2% effort funded. 10% contributed. National Community Pharmacists Association. 10/1/1998-9/30/1999. (Total Direct Cost = \$9,700).
6. Unbiased Outcome Estimates for Conservative vs. Aggressive Treatment of Early Stage Prostate Cancer from Retrospective Data: An Instrumental Variables Approach. Principal Investigator: Elizabeth Chrischilles. Co-investigator. 12% effort. 10/1/1998-3/1/2001. United States Department of Defense. (Total Direct Cost = \$298,803).
7. Determination of the Costs Associated with the Inpatient Treatment of Infections Caused by Gram-Positive Pathogens. 5% effort. Principal Investigator: Michael Klepser. Co-Investigator. 1/1/1999-9/30/1999. Pharmacia and Upjohn (Total Direct Cost = \$57,150).
8. Comparison of Two Linked Databases to Study Variation in Treatment Patterns of Breast Cancer. Principal Investigator: Brad Doebbeling. Co-Investigator. 5% effort. 7/1/1999-6/30/2000. National Cancer Institute (Total Direct Cost = \$68,650).
9. Evidence-Based Practice: From Book to Bedside. Principal Investigator: Mariita Titler. Co-Investigator. 10% effort. 10/1/1999-9/30/2002. Agency for Health Care Policy and Research. (Total Direct Cost = \$1,405,899).
10. Outsourcing VA Inpatient Care: Impact on Utilization, Quality, and Policy. Principal Investigator: Doug Wakefield. Co-Investigator. 10% effort. 3/1/2000-2/28/2002. Department of Veterans Affairs. (Total Direct Cost = \$300,000).
11. Economic Special Study Center. Co-Principal Investigator/Deputy Director: John Brooks 7.5% effort. 4/11/2000-10/29/2006. United States Renal Data System Special Studies Centers. (Total Direct Cost = \$884,970).

12. Program for Interdisciplinary Research in Health Care Organizations. Principal Investigator: Gary Rosenthal. Co-Investigator/Director Health Economics Core. 15% effort. 4/01/2001-3/31/2006. Department of Veterans Affairs. (Total Direct Cost = \$1,334,097).
13. The Marginal Benefits of Adjuvant Treatments for Early-Stage Non-Small-Cell Lung Cancer: Estimation and Validation Using Instrumental Variable Techniques. Principal Investigator. John Brooks. 15% effort. 09/01/2001-8/81/2006. National Cancer Institute. (Total Direct Cost = \$358,717).
14. Lung Cancer Care Outcomes/Surveillance Consortium of Iowa. Principal Investigator: Robert Wallace. Co-Investigator. 5% effort. 09/01/2001-8/81/2006. National Cancer Institute. (Total Direct Cost = \$2,040,437).
15. Impact of Patient and Provider Characteristics on the Treatment, Outcomes and Costs of Neutropenia among Patients with NHL. Principal Investigator: Elizabeth Chrsichilles. Co-Investigator. 15% effort. 11/12/2001-11/11/2002. Amgen (Total Direct Cost = \$159,998).
16. Impact of the Iowa Priority Brown Bag Medication Review on the Safety, Effectiveness and Efficiency of Seniors= Medication Use. Principal Investigator: Karen Farris. Co-Investigator. 03/31/2002-04/01/2002. 5% effort. Iowa Department of Public Health (Total Direct Cost = \$92,934).
17. Impact of Patient and Provider Characteristics on the Treatment, Outcomes and Costs of Neutropenia among Patients with NHL: Analysis of the National SEER-Medicare Linked Database. Principal Investigator: Elizabeth Chrischilles. Co-Investigator. 10% effort. 01/23/2003-01/22/2004. Amgen (Total Direct Cost = \$154,605).
18. Integrating Aging and Cancer Research. Principal Investigator: Robert Wallace. Co-Investigator. 10% effort. 9/29/2003-8/31/2008. National Institute of Health (Total Direct Cost = \$2,105,881).
19. Local Therapy of Breast Cancer in Community Populations. Principal Investigator: Nancy Keating. Co-Investigator. 15% effort. 04/05/2005-03/31/2006. Harvard/National Institute of Health. (Total Direct Cost = \$52,165).
20. University of Iowa Older Adults CERT. Principal Investigator: Elizabeth Chrsichilles. Co-Investigator. 10% effort. 07/01/2005-06/30/2010. Agency for Healthcare Research and Quality. (Total Direct Cost = \$2,787,229).
21. The Effects of Local Area Provider Supply and Access on Adjuvant Treatment Decisions for Lung and Colorectal Cancer Patients. Principal Investigator: John Brooks. 5% effort. National Cancer Institute. (Total Direct Cost = \$34,841).
22. Cardiac Care in Specialty and General Hospitals. Principal Investigator: Peter Cram. Co-Investigator. 20% effort. 05/01/2007-02/28/2011. Agency for Healthcare Research and Quality. (Total Direct Cost = \$1,849,060).

23. Effects of Oral Clefts on Birth Outcomes and Cleft Risks Due to Maternal Smoking. Principal Investigator: George Wehby. Co-Investigator. 10% effort. 08/01/09-07/31/2010. National Institute of Health. (Total Direct Cost = \$198,900).
24. Are Cardiovascular Medications Effective in ESRD? Principal Investigator: Theresa Shireman. Co-Investigator. 10% effort. 09/15/08-07/31/2012. National Institute of Health (Total Direct Cost = \$196,542).
25. Interventions to Improve Colon Cancer Screening in Poor Rural Iowa Counties. Principal Investigator: Barcey Levy. Co-Investigator. 5% effort. 07/01/2009-06/31/2011. American Cancer Society (Total Direct Cost = \$364,973).
26. A Collaborative Model to Improve Blood Pressure and Minimize Racial Disparities. Principal Investigator: Barry Carter. Co-Investigator. 5% effort. 04/15/09-02/28/2014. National Institute of Health. (Total Direct Cost = \$3,639,530).
27. Improving the Delivery of Smoking Cessation Guidelines for Hospitalized Veterans. Principal Investigator: David Katz. Co-Investigator. 5% effort. 10/01/09-09/30/2012. VA HSR&D (Total Direct Cost = \$899,600).
28. Improving Adherence to Blood Pressure Guidelines. Principal Investigator: Barry Carter. Co-Investigator. 20% effort. 08/01/2007-07/31/2010. National Institute of Health. (Total Direct Cost: \$2,389,022).
29. Comparative Effectiveness of FIT vs Colonoscopy for Colon Cancer Screening. Principal Investigator: Barcey Levy. Co-Investigator. 09/29/2009-09/30/2011. NIH/ARRA. 10% effort (Total Direct Cost: \$522,206).
30. Enhanced Continuity of Pharmacy Care for Cardiovascular Pulmonary Diseases. Principal Investigator: Barry Carter. Co-Investigator. 04/01/2009-03/31/2012. NIH. 10% effort (Total Direct Cost: \$716,427).
31. The Brigham and Women's Methods Network for Conducting Comparative Effectiveness Research. Principal Investigator: Sebastian Schneeweiss. 04/10/2010-03/31/2013. Agency for Healthcare Research and Quality. Task order contract.
32. Comparative Effectiveness of Treatment Combination Post-MI in the Elderly. Primary Investigator: John Brooks. 08/01/2010-05/31/2014. Agency for Healthcare Research and Quality. 25% effort (Total Direct Cost = \$1,046,224)
33. Enhanced Data to Accelerate Complex Patient Comparative Effectiveness Research. Primary Investigator: Elizabeth Chrischilles. 08/01/2010-07/31/2012. AHRQ. 2% effort (Total Direct Cost = \$887,569).
34. Developing Evidence to Inform Decisions about Effectiveness Research Network-2. Primary Investigator: Elizabeth Chrischilles. 08/10/2010-08/09/2013. AHRQ. Task Order Contract.

35. Should High-Risk Statin Utilization Rates Be Increased for Complex AMI Patients? Primary Investigator: John Brooks. 09/30/2010-09/29/2012. AHRQ. 20% (Total Direct Cost = \$333,174)
36. Interpreting IV Estimates with Treatment Effect Heterogeneity: ACE/ARBs & Race. Primary Investigator: John Brooks. 09/01/2010-08/31/2013. NIH. 20% (Total Direct Cost = \$1,478,096)
37. ARRA: University of Iowa Clinical and Translational Science Program. Primary Investigator: Gary Rosenthal. 08/05/2010-05/31/2012. NIH 10% (Total Direct Cost = \$22,889,384)
38. ASCO Study of Geographical Access to Oncology Care. Primary Investigator: Marcia Ward. 11/01/2010-06/01/2012. American Society of Clinical Oncology. 2% (Total Direct Cost = \$225,832)
39. Interpreting Treatment Estimates with Effect Heterogeneity Across Outcomes. PI: John Brooks. 01/01/2014-12/31/2017. 25% Patient Centered Outcomes Research Institute (PCORI) 20% (Total Direct Cost = \$842,832)
40. Development of Physical Therapy Performance Measure Algorithms. PI: John Brooks 01/01/2018-05/31/2018. Physical Therapy Industry (PTI) Outcomes Registry Workgroup. 35% (Total Direct Cost = \$141,000).
41. Effectiveness of a PT First Musculoskeletal Pathway. PI: Chuck Thigpen. Magistro Family Foundation. 01/01/2018-12/31/2019. 2.5% (Total Direct Cost = \$100,000).
42. An Integrated Approach to Reducing Post-Discharge Utilization. PI: Ronda Hughes. University of South Carolina Aspire II. 07/01/2018 – 09/30/2019. 7% (Total Direct Cost = \$97,551).

B.2 Research Support – Current

1. Effect of the patient-centered medical home on geographic and racial disparities in health care access. PI Nathaniel Bell. AHRQ 1R03HS026263-01A1. 09/01/2019 – 08/31/2021. Annual Direct Cost: \$33,556. Co-Investigator: 1% effort both years.

B.3 Research Support – Pending

1. Assessment of a Tailored Opioid Prescribing Guideline on Episode Opioid Utilization, Pain Management and Patient-Reported Outcomes. Co-Principal Investigators: Jeremy Warren, MD and Sarah Floyd, PhD. Co-Investigator. 04/01/2020—03/31/2021. Prisma Health-Upstate. (Total Direct Costs \$19,514.00).
2. Effects of Musculoskeletal Surgery Rate of Medicare Costs. Principal Investigator. 20% effort. 07/01/2020—06/30/2024. National Institute of Health. (AHRQ) (Total Direct Costs: \$1,013,213.00).

B.4 Research Support – Submitted/Not Funded in 2019

1. The Development of an Orthopaedic Rapid Learning Tool: A Step toward Personalized Comparative Effectiveness Decision Support. Principal Investigator: Sarah Floyd, PhD. Co-Investigator. 5% effort. 02/01/2020—01/31/2022. National Institute of Health (AHRQ). (Total Direct Costs: \$197,450.00).
2. Effect Heterogeneity of Early Surgery for Elderly Patients with Common Shoulder Conditions. Principal Investigator. 25% effort. 02/01/2020—01/31/2023. PCORI. (Total Direct Costs: \$1,276,368.00).
3. Effects of Musculoskeletal Surgery Rate of Medicare Costs. Principal Investigator. 25% effort. 10/01/2019—09/30/2022. National Institute of Health. (AHRQ) (Total Direct Costs: \$946,468.00).
4. The Development of a Rapid Learning Tool in Musculoskeletal Medicine: A Step toward Personalized Comparative Effectiveness Decision Support. Principal Investigator: Sarah Floyd, PhD. Co-Investigator. 4% effort. 07/01/2019—09/30/2020. University of South Carolina (ASPIRE II). (Total Direct Costs: \$92,256.00).

C. Peer-Reviewed Presentations (least to most recent)

1. **Brooks JM**, Kirking, D. *Measuring the Effect of Production Variation on Pharmacy Labor Demand*. Podium presentation at the annual meeting of the American Pharmaceutical Association in Seattle, Washington, March 19-23, 1994.
2. **Brooks JM**, Dor, A, Wong H. *The Hospital-Insurer Bargaining Process: Does Market Power Have a Role?* Poster presentation at the meeting of the American Public Health Association in San Diego, California, November 1, 1995.
3. **Brooks JM**, Dor A, Wong H. *Hospital-Insurer Interaction as a Bargaining Process: An Empirical Investigation of Appendectomy Pricing*, Podium presentation at the International Health Economics Association Inaugural Conference in Vancouver, British Columbia, Canada, May 21, 1996.
4. **Brooks JM**, McClellan, M, Wong H. *Estimating the Effectiveness of Invasive Treatments for Acute Myocardial Infarction Using Instrumental Variables Techniques: Does Insurance Status Matter?* Podium presentation at the 1997 International Conference on Health Policy Research, Crystal City, Virginia, December 6, 1997.
5. **Brooks JM**, Doucette W, Sorofman B. *Using the Impact of Medicaid and Managed Care on Retail Pharmacy Cash Prices to Reveal Pharmacy Objectives*. Podium presentation at the annual meeting of the American Pharmaceutical Association in Miami, Florida, March 21, 1998.
6. Doucette WR, **Brooks JM**, Sorofman BA, *Market Factors Associated with the Presence of Independent Pharmacies*, Podium presentation at the American Pharmaceutical Association Annual Meeting, Miami, FL; March 22, 1998.

7. **Brooks JM**, Sorofman B, Doucette W. *The Effect of Changes in Medicaid Reimbursement Levels on Prescription Prices for the Uninsured*. Poster presentation at the 1998 meeting of the Association for Health Services Research in Washington, D.C. June 22, 1998.
8. **Brooks JM**, Doucette W, Sorofman B. *Factors Affecting Bargaining Between Pharmacies and Insurers*. Podium presentation at the 1998 meeting of the Association for Health Services Research in Washington, D.C. June 22, 1998.
9. **Brooks JM**. *Estimating Treatment Effectiveness Using Instrumental Variable Estimation Techniques and Retrospective Data*. Podium presentation at the Wintergreen Research Conference V hosted by the Center on Drugs and Policy at the University of Maryland. May 7, 1999.
10. Ritho J, **Brooks JM**, *Treatment Variation Involving Adjuvant Chemotherapy in Early-Stage Breast Cancer Patients*. Podium presentation at the Wintergreen Research Conference V hosted by the Center on Drugs and Policy at the University of Maryland. May 7, 1999.
11. **Brooks JM**, Park TR, Klepser M. *Estimating the Cost-Effectiveness of Antibiotic Treatment for Acute Otitis Media Using Instrumental Variable Estimation Techniques*. Podium presentation at the 1999 International Society for Pharmacoeconomics and Outcomes Research Meeting, Crystal City, VA, May 24, 1999.
12. Doucette WR, **Brooks JM**, Sorofman BA, Wong H, *Market Influences on the Availability of Community Pharmacies in the U.S.*, Poster presentation at the Association for Health Services Research Annual Meeting, Chicago; June 27, 1999.
13. Ritho J, **Brooks JM**, Scott S. *Validation of Early Stage Breast Cancer Diagnosis and Treatment Involving Chemotherapy Using Linked Iowa/SEER Medicare Claims Data*. Podium presentation at the annual meeting of the American Pharmaceutical Association in Washington, D.C., March 11, 2000.
14. Ritho J, **Brooks JM**. *Assessing Adjuvant Chemotherapy Treatment Variation in Early Stage Breast Cancer Patients in Iowa Using Surveillance and Epidemiology and End Results (SEER) Program Database*. Podium presentation at the annual meeting of the American Pharmaceutical Association in Washington, D.C., March 11, 2000.
15. Doucette W, **Brooks JM**. *Influences on Bargaining Outcomes Between Independent Community Pharmacies and Third Party Payers*. Poster presentation at the annual meeting of the American Pharmaceutical Association in Washington, D.C., March 12, 2000.
16. **Brooks JM**, McDonough R, Doucette W. *Reimbursing Pharmacists for Pharmaceutical Care: Why Might Insurers Flinch*. Podium presentation at the annual meeting of the American Pharmaceutical Association in Washington, D.C., March 11, 2000.

17. **Brooks JM**, Doucette W. *The Impact of Pharmacy Bargaining Strategies on Pharmacy Bargaining Power*. Poster presentation at the annual meeting of the American Pharmaceutical Association in Washington, D.C., March 11, 2000.
18. Klepser D, Doucette WR, **Brooks JM**, *Changes in Market Factors and Their Effect on Community Pharmacy Availability*, Podium presentation at the Midwest Pharmacy Administration Conference, Toledo, OH; July 28, 2000.
19. Klepser M, Klepser D, **Brooks JM**, Ernst E, Diekema D, Hoffman H, Mozaffari E, Hendrickson J, Doern G. *Examination of Healthcare Resource Utilization Associated with the Treatment of Infections Caused by Susceptible and Non-susceptible isolates of Streptococcus Pneumoniae*. Podium presentation at the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ontario. September 20, 2000.
20. **Brooks JM**, Chrischilles E, Scott S, Ritho J, Chen-Hardee S. *Instrumental Variable (IV) Estimates of Survival Impacts of Surgical Choice for Marginal Early Stage Breast Cancer (ESBC) Patients in Iowa*, Poster presentation at National Conference for Techniques for Handling Bias in Health Services Outcomes Research hosted by Houston Department of Veterans Affairs, November 9, 2000.
21. Shetty S, **Brooks JM**, Perry P, Momany E, Lund B. *Factors Associated with the Use of Atypical Antipsychotic Agents in the Iowa Medicaid Population*. Poster presentation at the annual meeting of the American Pharmaceutical Association in San Francisco, CA March 16, 2001.
22. Kleusner M, **Brooks JM**, *Factors Affecting the Use of Stimulants Post-ADHD Diagnosis*. Poster presentation at the annual meeting of the American Pharmaceutical Association in San Francisco, CA March 16, 2001.
24. Klepser M, Klepser D, **Brooks JM**, Ernst E, Diekema D, Hoffman H, Mozaffari E, Hendrickson J, Doern G. *Determination of the Costs Associated with the Inpatient Treatment of Infections Caused by Staphylococcus Aureus*. Poster presentation at the annual meeting of the American Pharmaceutical Association in San Francisco, CA March 16, 2001.
25. Park TP, **Brooks JM**. *Antibiotic Treatment Patterns for the Treatment of Initial Acute Otitis Media in Children Enrolled in Iowa Medicaid from 1990 through 1997*. Poster presentation at the 2001 International Society for Pharmacoeconomics and Outcomes Research Meeting, Crystal City, VA, May 21, 2001.
26. **Brooks JM**, Chrischilles E, Scott S, Cehn-Hardee S, Konety BR. *Effectiveness of Aggressive Treatments for Early-Stage Prostate Cancer: Evidence from SEER-Medicare Using Instrumental Variables Estimation*. Moderated Poster presentation at the American Urology Association Meetings, Orlando, FL, May 26, 2002.
27. Shetty S, **Brooks JM**. *Influence of Physician Mix and Supply on the Diffusion of Atypical Antipsychotic Agents*. Podium presentation at the 2002 Midwest Pharmacy Administration Conference, Ann Arbor, MI, July 22, 2002.

28. Park TR, **Brooks JM**. *Factors Affecting the Initial Diagnosis of Acute Otitis Media in Iowa Medicaid Children*. Poster presentation at the 2002 Midwest Pharmacy Administration Conference, Ann Arbor, MI, July 22, 2002.
29. **Brooks JM**, Klepser DG, Chrischilles EA, Voelker MD, Chen-Hardee SS, Scott SD, Link BK, Delgado DJ. Effect of clinical factors on neutropenia-related inpatient charges among newly diagnosed non-Hodgkin's lymphoma (NHL) patients during first course chemotherapy. Abstracts of the 39th Annual Meeting of the American Society of Clinical Oncology (poster), Chicago, Illinois, May 31-June 3, 2003.
30. Chrischilles EA, Voelker MD, Chen-Hardee SS, **Brooks JM**, Scott SD, Link BK, Delgado DJ. Time to First Neutropenia Hospitalization During Chemotherapy for Non-Hodgkin's Lymphoma: an Iowa SEER-Medicare study. Abstracts of the 39th Annual Meeting of the American Society of Clinical Oncology (poster), Chicago, Illinois, May 31-June 3, 2003.
31. **Brooks JM**, Voelker MD, Chen-Hardee SS, Park T, Wright KB, Link BK, Chrischilles EA, Rubenstein LM, Delgado DJ. Neutropenia-Related Inpatient Medicare Costs During First Course Chemotherapy Among Newly Diagnosed Non-Hodgkin s Lymphoma Patients National SEER-Medicare Study. The Annual Meeting of the American Society of Hematology (poster), San Diego, CA, December 6, 2003.
32. Chrischilles EA, Rubenstein LM, Voelker MD, Wright KB, Link BK, **Brooks JM**, Delgado DJ. Granulocyte Colony-Stimulating Factor Use During First Course Chemotherapy for Non-Hodgkin s Lymphoma National SEER-Medicare Study. The Annual Meeting of the American Society of Hematology (poster), San Diego, CA, December 6, 2003.
33. Voelker MD, Rubenstein LM, Chrischilles EA, Chen-Hardee SS, Link BK, Wright KB, **Brooks JM**, Delgado DJ. Time to First Neutropenia Hospitalization During First Course Chemotherapy Among Newly Diagnosed Non-Hodgkin s Lymphoma Patients: National SEER-Medicare Study. The Annual Meeting of the American Society of Hematology (oral), San Diego, CA, December 6, 2003.
34. **Brooks JM**, Zhao Y, Chrischilles EA, Pendergast JF, Flanigan MJ, Hunsicker LG. Hemodialysis Provider Characteristics and Early Initiation of Hemodialysis. 36th Annual Meeting and Scientific Exposition of the American Society of Nephrology (poster), San Diego, CA, November 13, 2003.
35. **Brooks JM**, Irwin CP, Pendergast JF, Flanigan MJ, Hunsicker LG. Effect of Dialysis Center Profit Status on Patient Survival An Instrumental Variable Approach. 36th Annual Meeting and Scientific Exposition of the American Society of Nephrology (poster), San Diego, CA, November 13, 2003.
36. Zhao Y, **Brooks JM**, Chrischilles EA, Flanigan MJ, Pendergast JF, Hunsicker LG. Factors Influencing PRE-ESRD Anemia Treatment in Elderly Hemodialysis Patients. American Pharmacists Association Meeting. Orlando, FL, April 2005.
37. **Brooks JM**, Chrischilles EA, Chen-Hardee S, Scott SD, "Estimating the Effectiveness of Early-Stage Lung Cancer Adjuvant Treatments Using Instrumental Variable Methods",

- Meeting of the International Society of Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 2006.
38. Zhao Y, **Brooks JM**, Chrischilles EA, Pendergast JF, Hunsicker LG. "Factors Influencing Early Nephrology Care Prior to Hemodialysis Initiation Among Elderly Patients with End-Stage Renal Disease", Meeting of the International Society of Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 2006.
 39. John E, Farris KB, **Brooks JM**. "The Effect of Medications on the Visit Time with Physicians: Results from the NAMCS Survey", Meeting of the International Society of Pharmacoeconomics and Outcomes Research, Philadelphia, PA, May 2006.
 40. **Brooks JM**, Chrischilles EA, Chen-Hardee S, Scott SD, "Cost-Effectiveness of Early-Stage Lung Cancer Adjuvant Treatments Using Instrumental Variables," Podium Presentation at the Inaugural Meeting of the American Society of Health Economics. Madison, Wisconsin. June 2006.
 41. **Brooks JM**, Chrischilles EA, Wright K, Voelker MD, Chen-Hardee S. "Contrasting Interpretations of Treatment Effect Estimates Between RA and IV Approaches: Aggressive Treatment of Early-Stage Prostate Cancer". Podium Presentation at the Agency for Healthcare Research and Quality's DEClDE Program Symposium: Comparative Effectiveness and Safety: Emerging Methods. June 2006.
 42. Urmie J, Chrischilles EA, Weeks J, **Brooks JM**, Pendergast J, Provenzale D, Nerenz D, West D. Preferences and Beliefs of Lung and Colorectal Patients: The Role of Demographic and Socio-Economic Variables. Academy Health Meeting, June 2006.
 43. Wan S, **Brooks JM**, Chrischilles EA, Wright K. "Effect of Hospice Access on the Use of Hospice Among Patients with Metastatic Breast Cancer", Poster presentation at the American Public Health Association Meeting, Washington DC, Nov 3-7, 2007.
 44. Zhao, Y, **Brooks JM**, Flanigan MJ, Chrischilles EA, Pendergast JF, Hunsicker LG, "Short-term survival effect of early nephrology care prior to dialysis initiation in elderly patients with end-stage renal disease." Poster presentation at the National Kidney Foundation Spring Clinical Meeting, Orlando, FL, April 10-14, 2007.
 45. Pan X, **Brooks JM**, Wright K, "Influence of Medicare Claim-Paying Agents' Reimbursement Policy on G-CSF Choice during First Cycle of Chemotherapy for NHL Patients," Podium at the International Society of Pharmacoeconomics and Outcomes Research, Toronto, Ontario, Canada, May 5, 2008.
 46. Polgreen LA, **Brooks JM**, "Estimation Comparisons of Linear Cost Models with Skew," Podium presentation at the American Society of Health Economists Biennial Meeting, Durham, NC, June 24, 2008.
 47. Ohsfeldt RL, Summers KH, **Brooks JM**, Brewster C, Lage MJ, "Differences in Treatment Costs and Resource Utilization Among COPD Patients Treated with Albuterol MDI or Levalbuterol MDI," poster presentation at the International Society of

- Pharmacoeconomics and Outcomes Research 11th Annual European Congress, Athens, Greece, November 9, 2008.
48. Xie Y, **Brooks JM**, Urmie JM, Doucette WR, “Bargaining Between Prescription Drug Plans and Independent Pharmacies Under Medicare Part D” poster at the International Health Economics Association Meetings, Beijing China, July 13, 2009.
 49. Xie, Y, Urmie, **Brooks, JM**, Doucette WR, Independent Retail Pharmacy Attributes, Insurer Reimbursement, and the Implication on the Proposed Collective Bargaining Law, VALUE IN HEALTH Volume: 13 Issue: 3 Pages: A100-A100 Published: 2010
 50. Kulchaitanaroaj P, **Brooks JM**, Ardery G, Newman D., Carter BL., Cost of physician and pharmacist collaboration to improve blood pressure control. Podium presentation, Midwest Social and Administrative Pharmacy Conference, Iowa City, IA, 2010.
 51. Tang Y, Xie Y, **Brooks JM**, Doucette WR, Urmie JM. Does bargaining affect Medicare prescription drug plan reimbursements to independent pharmacies? Midwest Social and Administration Conference, Iowa City, IA, July 29, 2010 (Preliminary results).
 52. Kulchaitanaroaj P, **Brooks JM**, Ardery G, Newman D., Carter BL., Direct Costs of Physician and Pharmacist Collaboration to Improve Blood Pressure Control. Podium Presentation, APhA Annual meeting.
 53. Kulchaitanaroaj P, **Brooks JM**, Carter BL, Ardery G, Applying Instrumental Variable Estimators to Randomized Interventions: The Effect of Added Pharmacist Time on Blood Pressure Reduction and Costs. Podium Presentation, International Health Economics Association Conference (iHEA), Toronto, Canada, 2011.
 54. Chapman CG, **Brooks JM**, Fu AC. The Influence of Local-Area Physician Supply on Dispersion of Care among Medicare Patients with Consistent Diagnosis. IHEA, Toronto, Canada, July 2011.
 55. Tang Y, Fang G, Newman DM, Nguyen E, **Brooks JM**, Shireman TI. Variation in cardiovascular prescription drug use across states. International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Chicago, IL, August 15, 2011.
 56. Tang Y, Fang G, Newman DM, Nguyen E, **Brooks JM**, Shireman TI. Small Area Variation in Cardiovascular Prescription Drug Use across the United States among Medicaid and Medicare Dual-Eligible Beneficiaries. American Pharmacists Association Annual Meeting, New Orleans LA; March 12, 2012.
 57. Kulchaitanaroaj P, **Brooks JM**, Carter BL, Ardery G, The Effect of Pharmacist Time in Physician-Pharmacist Collaboration on Blood Pressure Reduction and Costs—Comparing Estimates between Multiple Linear Regression and Instrumental Variable Regression. Podium Presentation, APhA Annual meeting, New Orleans LA; March 12, 2012.

58. Tien Y, Link B, **Brooks JM**, Wright K, Chrischilles EA. Diffuse Large B-Cell Lymphoma (DLBCL) in the Elderly: Use of Chemotherapy and Rituximab and Associated Survival. Health Sciences Research Week at University of Iowa; April 3, 2012.
59. Chapman CG, **Brooks JM**, Fu AC, L Polgreen. Estimating the Effect of the Dispersion of Care across Physicians on Costs and Outcomes. ASHEcon, Minneapolis, MN June 2012.
60. **Brooks JM**. Conditions Required to Identify Alternative Treatment Effect Estimates Using IV Estimators. ASHEcon, Minneapolis, MN June 2012.
61. **Brooks JM**, Tang Y, Chapman CG, Cook EA, Chrischilles EA. Using Local Area Practice Style Measures as Instruments: Does the Definition of “Local” Matter? 4th DEcIDE Symposium on Comparative Effectiveness Methods: From Efficacy to Effectiveness, Rockville, MD June 2012.
62. Chapman CG, **Brooks JM**. Fragmentation of Prescribing. Midwest Social Administrative Pharmacy Conference. Madison, WI. June 2012.
63. Schroeder MC, Sugg SL, **Brooks JM**, Thomas A. “Surgical Management of Breast Cancer: Breast Conserving Surgery or Mastectomy in the 2010 SEER Registries by Hormone Receptor and HER2 Status.” *Cancer Research*, 73(24_Supplement):P2-18-12. (2013 San Antonio Breast Cancer Symposium, poster presentation)
64. Schroeder MC, Tien Y, Halfdanarson TR, Abu-Hejleh T, Nattinger M, **Brooks JM**. “Geographic Variation in the Adjuvant Treatment of NSCLC over Time.” *Journal of Clinical Oncology*, 31(15_suppl):6542. (2013 American Society of Clinical Oncology Annual Meeting, poster presentation)
65. Tien Y, Schroeder MC,* Wright K, Halfdanarson TR, Abu-Hejleh T, Nattinger M, **Brooks JM**. “Geographic Variation in the Use of Adjuvant Radiation and Chemotherapy Among Elderly Patients with Resected Non-Small Cell Lung Cancer.” *Journal of the American Pharmacists Association*, 53(2):e115(#293). (2013 American Pharmacists Association Annual Meeting, podium presentation)
66. Schroeder MC, Tien Y, Thomas A, Keating NL, **Brooks JM**. “Comparative Effectiveness of Four Treatment Modalities for Early Stage Breast Cancer Patients.” *Cancer Research*, 73(24_Supplement): P5-15-01. (2013 San Antonio Breast Cancer Symposium, poster presentation)
67. Chapman CG, **Brooks JM**, Cook EA, Chrischilles EA. Variation in Statin Intensity Prescribing Post-Acute Myocardial Infarction by Baseline Patient Complexity. 19th Annual ISPOR Meeting, New Orleans, May 2013.
68. Schroeder MC, Goedken AG, **Brooks JM**. “The Effect of Medicaid Reimbursement Generosity on Physician Access: Diagnosing of Asthma in Children,” podium presentation, Association for Public Policy Analysis and Management Fall Research Conference, November 2014.

69. Schroeder MC, Zhang Y, **Brooks JM**. "Pharmacist Billing in Medicare Part A and Part B Claims." *Journal of the American Pharmacists Association*, 54(2):e85(#27). (2014 American Pharmacists Association Annual Meeting, podium presentation)
70. Schroeder MC, Goedken AG, **Brooks JM**. "The Effect of Medicaid Reimbursement Generosity on Physician Access: Diagnosing of Asthma in Children," podium presentation, American Society of Health Economists Biennial Conference, June 2014.
71. Middendorff G, Lund B, Schroeder MC, **Brooks JM**. "The Effect of Hospitalization and Regional Geography on the Use of Potentially Inappropriate Medications in Older Adults." *Journal of the American Pharmacists Association*, 54(2):e109(#92). (2014 American Pharmacists Association Annual Meeting, oral poster presentation)
72. Chapman CG, **Brooks JM**. Robustness and Interpretability of Treatment Effect Estimates Generated by Nonlinear 2SRI in Alternative Models of Treatment Effect Heterogeneity and Choice. 5th Biennial Conference of ASHEcon. June 2014.
73. Tang Y, Kauer J, Schroeder MC, Wehby G, Doucette W, **Brooks JM**. "Geographic Variation in Depression Diagnosis Among Medicare Beneficiaries with Acute Myocardial Infarction," *Value in Health*, 18(3):A52. (2015 International Society for Pharmacoeconomics and Outcomes Research Annual International Meeting, poster presentation)
74. Schneider KM, Wilwert J, Chrischilles EA, Schroeder MC, Lee MJ, Chapman C, Brooks JM. "Variation in Treatment for Acute Stroke by Pre-Hospitalization Functional Status," poster presentation, American Public Health Association Annual Meeting and Expo, October 2016.
75. Schroeder MC, Schneider KM, Chrischilles EA, O'Donnell BE, **Brooks JM**. "Are Disparities in Use of Guideline Medications Post-AMI Driven by Patient Nonadherence?" *Journal of the American Pharmacists Association*. 56(3):e1(#1). (2016 American Pharmacists Association Annual Meeting, podium presentation)
76. Floyd SB, Campbell J, Thigpen CA, Kissenberth M, **Brooks JM**. (2018, April) Geographic Variation in the Treatment of Proximal Humerus Fracture in the Medicare Population. Greenville Health System Research Showcase, Greenville, SC.
77. Thigpen CA, **Brooks JM**, Floyd SB, Kissenberth MJ, Hawkins RJ, Tokish JM. (2017, October) A risk adjusted performance measure to compare surgeons for patients following rotator cuff repair. AAOS Annual Meeting, San Diego, CA.
78. Floyd SB, Matthia E, Chapman CG, **Brooks JM**. (2017, March) Patient characteristics and treatment utilization for shoulder osteoarthritis: variation at the local and national level. Greenville Health System Research Showcase, Greenville, SC.
79. Chapman CG, Floyd SB, Thigpen CA., **Brooks JM**, Tokish JM. (2017, March) Treatment for rotator cuff tear heavily influenced by demographics and where patients live. Greenville Health System Research Showcase, Greenville, SC.

E. Invited Presentations (least to most recent)

1. **Brooks JM.** *Public Health and Prevention: Who Benefits and Who Pays?*, Podium presentation at the Agency for Health Care Policy and Research sponsored conference Promoting Public Health in an Era of Change in Towson, Maryland, July 17, 1996; Denver, Colorado July 17, 1997.
2. **Brooks JM,** Doucette W, Sorofman, B. *Factors Affecting Bargaining Between Pharmacies and Insurers.* Podium presentation to the National Community Pharmacist Association Bargaining Task Force, Pittsburgh, PA, May 6, 1998.
3. **Brooks JM,** McDonough R, Doucette W. *Reimbursing Pharmacists for Pharmaceutical Care: Why Might Insurers Flinch.* Podium presentation at the 1999 Midwest Pharmacy Workforce Conference, Minneapolis, MN. October 28, 1999.
4. **Brooks JM.** *Psychotherapeutic Drug Use in the Iowa Medicaid Population: A Panel Data Study.* Podium presentation to the Iowa Drug Utilization Review Commission. February 2, 2000.
5. **Brooks JM.** *Using Instrumental Variable Techniques to Estimate Treatment Effectiveness.* Podium presentation at the annual meeting of the Drug Information Association in San Diego, California, June 12, 2000.
6. **Brooks JM,** Chrischilles E, Scott S, Ritho J, Chen-Hardee S. *Is Lumpectomy Underused for Early Stage Breast Cancer (ESBC) Patients: Evidence Using Instrumental Variable Estimation.* Lister Hill Center for Health Policy Seminar Series. University of Alabama Birmingham, October 10, 2001.
7. **Brooks JM,** Manning W, Collins A, Li S. *Comparing Medicare Costs for CKD and non-CKD and Dialysis Patients.* Podium presentation at the annual meeting of the American Society of Nephrology in Philadelphia PA, November 2, 2002.
8. **Brooks JM.** *Estimating Treatment Effects with Observational Data using Instrumental Variable Estimation: The Extent of Inference*". Academy Health Meetings, San Diego, CA, June 8, 2004.
9. **Brooks JM.** *Estimating Treatment Effects with Observational Data using Instrumental Variable Estimation: The Extent of Inference*". Academy Health Meetings, Boston MA, June 26, 2005.
10. **Brooks JM,** Chrischilles EA, Wright KB, Voelker MD, Scott SD, Chen-Hardee SS, *Estimating the Effectiveness of Aggressive Treatments for Early Stage Prostate Cancer Using SEER-Medicare Databases (Preliminary Results),* University of Iowa Cancer Center. September 20, 2005.
11. **Brooks JM.** *Estimating Treatment Effects with Observational Data using Instrumental Variable Estimation: The Extent of Inference (Encore).* Cancer and Aging Program, University of Iowa. September 30, 2005.

12. **Brooks JM.** *The Available Concepts Within an Economic Model of Treatment Choice to Model Decision-Making in Healthcare.* Presented at Conference on Aging, Decision Making, and Cancer: An Invitation for Multidisciplinary Research. Cancer and Aging Program, University of Iowa, November 4, 2005.
13. **Brooks JM,** Doucette WR, Wan S, Klepser DG, *Factors Affecting Retail Pharmacy Market Structure and Performance.* Agency for Healthcare Quality and Research – AHRQ MarketNet Conference, November 10, 2005.
14. **Brooks JM,** Chrischilles EA, Chen-Hardee SS, Scott SD, Urmie JM, Doucette WR, *The Marginal Benefits of Adjuvant Treatments for Early-Stage Non-Small-Cell Lung Cancer: Estimation and Validation Using Instrumental Variable Techniques,* Cancer Care Outcomes Research and Surveillance Consortium semi-annual meeting. March 3, 2005.
15. **Brooks JM,** *Contrasting Interpretations of Treatment Effect Estimates Between Risk Adjustment (RA) and Instrumental Variable (IV) Approaches,* University of Southern California, April 6, 2007.
16. **Brooks JM,** *Heterogeneity and the Contrasting Interpretations of Risk Adjustment and Instrumental Variable Estimates,* University of Michigan, April 5, 2007.
17. **Brooks JM,** *Heterogeneity and the Contrasting Interpretations of Risk Adjustment and Instrumental Variable Estimates,* University of Kansas, August 8, 2007.
18. **Brooks JM,** *Estimating Treatment Effects for Binary Outcomes with Choice and Heterogeneity: A Simulation Model,* University of Southern California, October 17, 2009.
19. **Brooks JM,** *Interpreting Treatment Effect Estimates with Heterogeneity and Choice: Simulation Model Results (or Who the Heck is Heckman?),* University of Iowa College of Public Health, February 12, 2009.
20. **Brooks JM,** *The Need for Promoting Novel Analytical Approaches for Comparative Effectiveness Research,* Institute of Medicine Committee on Comparative Effectiveness Research Priorities, invited testimony, March 20, 2009.
21. **Brooks JM,** *Interpreting Treatment Effect Estimates with Heterogeneity and Choice: The Economic Perspective of CER,* Centers for Education & Research on Therapeutics, National Steering Committee Meeting, June 4, 2009.
22. **Brooks JM,** *Interpreting Treatment Effect Estimates with Heterogeneity and Choice: Simulation Model Results (or Who the Heck is Heckman?),* University of Iowa Public Policy Center, May 8, 2010.
23. **Brooks JM,** *Instrumental Variables and the Extent of Inferences from Observational Data,* University of Mississippi, April 28, 2011.
24. **Brooks JM,** *Instrumental Variables and the Extent of Inferences from Observational Data,* University of Arizona, March 14, 2012.

25. **Brooks JM**, *Variation in Statin Use After AMI: Evidence of Patient-Centered Care or Violation of Effective Care?* University of Chicago, April 23, 2014.
26. **Brooks JM**, *Can We Figure Out “Which Rate is Right” in Healthcare?* South Carolina Engenuity Science Café. Columbia SC. January 13, 2015.
27. **Brooks JM**, *Treatment Effect Inferences Using Observational Data when Treatment Effects are Heterogeneous Across Outcomes: Simulation Evidence.* Eastern North American Region International Biometric Society, Miami FL. March 16, 2015.
28. **Brooks JM**, *Statin Use After Acute Myocardial Infarction by Patient Complexity: Are the Rates Right?* Emory University. May 1, 2015.
29. **Brooks JM**, *Understanding Treatment Effect Estimates When Treatment Effects are Heterogeneous for More Than One Outcome: Simulation Evidence.* International Society for Pharmacoepidemiology, Mid-Year Meeting. Baltimore, MD April 11, 2016.
30. **Brooks JM**, *Data Needed to Assess Value-Based Musculoskeletal (MSK) Care*, Care Coordination Institute. Annual Meeting. Greenville SC April 25, 2017.
31. **Brooks JM**, *Use of ACEI/ARBs for Geriatric Ischemic Stroke Patients: Are the Rates Right? Inaugural talk in the ASPHG-USCMSG research series.* Greenville SC May 14, 2018.

VI. RECORD OF SERVICE ACTIVITIES

A. Editorships and Reviewer of Journals or Other Scholarly Publications

REVIEWER - Periodicals

Journal of Health Economics
Health Economics
Medical Care
AHRQ DECIDE Research Network
Inquiry
Circulation
Clinical Therapeutics
Contemporary Economic Policy
Pharmacoeconomics
Value in Health
Research in Social and Administrative Pharmacy
Journal of Clinical Epidemiology
American Journal of Epidemiology
Cancer
Health Care Financing Review
Health Services Research
Journal of the American Medical Association

*Journal of the American Pharmacists Association
Empirical Economics*

REVIEWER - Conference Abstracts and Papers

2000 Midwest Pharmacy Administration Biannual Meeting
2001 - 2007 American Pharmacist Association Annual Meeting, ESAS section
2001 - 2004 International Society for Pharmacoeconomics and Outcomes Research

REVIEWER – Grant Review Committees

2004 AHRQ Health Systems Research Study Section ad hoc member
2009 AHRQ Health Care Quality and Effectiveness Research Study Section ad hoc member
2009 Challenge Grant Mail Reviewer
2010 AHRQ Medical Liability and Safety Demonstration Projects (R18)
2010 AHRQ Developing Prospective Practice-based Comparative Effectiveness Research Clinical Registries: Orthopedic Devices, Drugs, and Procedures
2012-2017 AHRQ Healthcare Systems and Value Research (HSVR) Study Section Standing Member

B. Offices Held and Other Service to Professional Organizations

INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH

2000 - 2003 Retrospective Database Task Force Member
2001 Presentation Award Judge
2003 – 2006 Best Paper Award Chair
2008 North American Meeting Scientific Program Committee Co-Chair

C. Divisional, Collegiate, or University Service

UNIVERSITY OF IOWA

DIVISIONAL SERVICE

1997-1998 Faculty Search Committee Member
2001-2002 Faculty Search Committee Member
2004-2006 Faculty Search Committee Member
2004-2009 Director of the Program in Pharmaceutical Socioeconomics

COLLEGIATE SERVICE

1998-2004 Equipment Committee Member
1999 College Retreat Planning Committee Member
1999-present College of Public Health Faculty Search Committee Member
2002-2004 Chair of Assessment Committee

2005-present Chair of Graduate Education and Research Committee

UNIVERSITY SERVICE

2012 Member Biological Sciences Funding Program (BSFP) review committee

UNIVERSITY OF SOUTH CAROLINA

DIVISIONAL SERVICE

2014-2015 Faculty Search Committee Member

2015-2016 Faculty Search Committee Member

COLLEGIATE SERVICE

2015-2017 Research Advisory Council

2013-2018 Director of the Center for Effectiveness Research in Orthopaedics